Loading...
Association of Genetic Polymorphisms With Afatinib-induced Diarrhoea
Background/Aim: Afatinib, a 2(nd) generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) used in treatment of non-small cell lung cancer (NSCLC), causes diarrhoea in over 90% of patients. The association of genetic background with diarrhoea is poorly understood. Patients an...
Saved in:
| Published in: | In Vivo |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
International Institute of Anticancer Research
2020
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7279839/ https://ncbi.nlm.nih.gov/pubmed/32354939 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21873/invivo.11922 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|